Oramed Receives $18M Payment from Scilex, Approves $0.25/Share Cash Dividend

summarizeSummary

Oramed Pharmaceuticals announced it received an $18 million payment from Scilex Holdings, fully satisfying an option agreement, and subsequently approved a $0.25 per share cash dividend, totaling approximately $10.5 million, to reward stockholders.

check_boxKey Events

• Received $18 Million Payment

  Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings Inc., fully satisfying obligations under an Option Agreement and bringing total returns from its Scilex investment to $118 million.

• Approved Cash Dividend

  The Board of Directors approved a cash dividend of $0.25 per share, totaling approximately $10.5 million, to be paid on January 26, 2026, to stockholders of record as of January 16, 2026.

• Funded by Surplus Capital

  The dividend will be funded with surplus capital, highlighting the company's strong financial position and commitment to shareholder returns.

auto_awesomeAnalysis

Oramed Pharmaceuticals announced a significant financial boost by receiving an $18 million payment from Scilex Holdings, fully satisfying an option agreement and bringing total returns from its Scilex investment to $118 million. This substantial cash inflow, representing a material portion of the company's market capitalization, demonstrates successful capital allocation. Following this, the Board approved a $0.25 per share cash dividend, totaling approximately $10.5 million, which is a considerable return of capital to shareholders. This dividend, funded by surplus capital and declared while the stock is trading near its 52-week high, signals strong financial health and management's confidence, potentially enhancing investor appeal and attracting income-focused investors.